Citations

Clear

6273 citation(s) found for "To, Andrew".

The effect of plasma exchange on serum levels of lacosamide: A case report
Peters, Bradley J. , Brown, Andrew E. , Thornton, Nathaniel M, Chalmers, Sarah , Chalmers, Sarah J, Thornton, Nathaniel M, Winters, Jeffrey L.

Mayo Clinic

American Journal of Health-System Pharmacy | September 15, 2023 | Volume: 80 | Issue: 24 | Pages: 1781-1786

10.1093/ajhp/zxad224 | PMID 37712141 Get It

Abstract Purpose We describe the case of a 22-year-old male who developed thyroid storm necessitating therapeutic plasma exchange (TPE). The patient’s past medical history was complicated by epilepsy, for which he took lacosamide. Little evidence was available to guide lacosamide dosing during TPE. Because of an exacerbation of the patient’s underlying epilepsy in the context of the thyroid storm, we conducted therapeutic medication monitoring of lacosamide concentrations to guide management. Summary We arranged for measurement of the lacosamide concentration immediately before TPE (5.1 μg/mL) and 2.5 hours after the initial measurement (3.4 μg/mL) to determine the amount of lacosamide removed by TPE. Utilizing population pharmacokinetic parameters, we calculated the expected concentration and compared this to the measured concentration. The difference between these values was used to determine the percentage removed via TPE compared to the expected post-TPE concentration. We found that one TPE session removed an additional 20% of serum lacosamide. Conclusion TPE appeared to remove an additional 20% of lacosamide when compared to the expected post-TPE concentration.
Germline BRCA testing in pancreatic cancer: improving awareness, timing, turnaround, and uptake
Golan, Talia , Casolino, Raffaella , Hammel, Pascal, Whitaker, Kristen , Hall, Michael J. , Riegert‐Johnson, Douglas L. , Riegert-Johnson, Douglas L, Biankin, Andrew V. , Hammel, Pascal

Mayo Clinic

Therapeutic Advances in Medical Oncology | September 15, 2023 | Volume: 15 | Issue: No issue available | Pages: No page available

10.1177/17588359231189127 | PMID 37720496 Get It

Prognosis is generally poor for patients with pancreatic ductal adenocarcinoma. However, patients with germline BRCA1 or BRCA2 mutations (gBRCAm) may benefit from first-line platinum-based chemotherapy and maintenance therapy with the poly(adenosine diphosphate-ribose) polymerase inhibitor olaparib following at least 16 weeks of first-line platinum-based chemotherapy without disease progression. Germline breast cancer gene (BRCA) testing is therefore important to ensure that patients receive the most effective treatment. In addition, testing for other DNA damage response gene mutations beyond gBRCAm may also guide treatment decisions. However, clinical pathways for genetic testing are often suboptimal, leading to delays in treatment initiation or missed opportunities for personalized therapy. Barriers to testing include low rates of referral and uptake, delays to referral and slow result turnaround times, cost, and biopsy and assay limitations if somatic testing is performed, leading to the requirement for subsequent dedicated germline testing. Low rates of referral may result from lack of awareness among physicians of the clinical value of testing, coupled with low confidence in interpreting test results and poor availability of genetic counseling services. Among patients, barriers to uptake may include similar lack of awareness of the clinical value of testing, anxiety regarding the implications of test results, lack of insurance coverage, fear of negative insurance implications, and socioeconomic factors. Potential solutions include innovative approaches to testing pathways, including ‘mainstreaming’ of testing in which BRCA tests are routinely arranged by the treating oncologist, with the involvement of genetic counselors if a patient is found to have a gBRCAm. More recently, the utility of multigene panel analyses has also been explored. Access to genetic counseling may also be improved through initiatives such as having a genetic counseling appointment for all new patient visits and telemedicine approaches, including the use of telephone consultations or DVD-assisted counseling. Educational programs will also be beneficial, and cost effectiveness is likely to improve as the number of targeted treatments increases and when the earlier detection of tumors in family members following cascade testing is considered.
Mental Health Questions on State Medical License Applications and Evaluation of Updates
Douglas, Rachel N., Saddawi‐Konefka, Daniel , Hanson, Andrew C. , Pulos, Bridget P. , Kraus, Molly, Pulos, Bridget, Sharpe, Emily E. , Kraus, Molly B.

Mayo Clinic

JAMA Network Open | September 12, 2023 | Volume: 6 | Issue: 9 | Pages: e2333360

10.1001/jamanetworkopen.2023.33360 | PMID 37698865 Get It

This cross-sectional study evaluates the consistency of US medical license renewal applications with the Federation of State Medical Boards recommendations for questions regarding physician mental health.
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022
Veitch, Dallas P. , Weiner, Michael W. , Miller, Melanie J. , Aisen, Paul, Ashford, Miriam A., Harvey, Danielle , Jack, Clifford R. , Jagust, William J. , Landau, Susan, Morris, John C. , Nosheny, Rachel L. , Okonkwo, Ozioma C. , Perrin, Richard J. , Petersen, Ronald C. , Saykin, Andrew J. , Shaw, Leslie M. , Tosun, Duygu , Initiative, for the Alzheimer's Disease Neuroimaging, Jack, Clifford R , Saykin, Andrew J , Morris, John C , Harvey, Danielle J , Tosun, Duygu , Ashford, Miriam T. , Beckett, Laurel , Green, Robert C. , Nho, Kwangsik T. , Mindt, Mónica Rivera , Toga, Arthur W. , Initiative, for the Alzheimer's Disease Neuroimaging

Mayo Clinic

Alzheimer's & Dementia | September 12, 2023 | Volume: 20 | Issue: 1 | Pages: 652-694

10.1002/alz.13449 | PMID 37698424 Get It

AbstractThe Alzheimer's Disease Neuroimaging Initiative (ADNI) aims to improve Alzheimer's disease (AD) clinical trials. Since 2006, ADNI has shared clinical, neuroimaging, and cognitive data, and biofluid samples. We used conventional search methods to identify 1459 publications from 2021 to 2022 using ADNI data/samples and reviewed 291 impactful studies. This review details how ADNI studies improved disease progression understanding and clinical trial efficiency. Advances in subject selection, detection of treatment effects, harmonization, and modeling improved clinical trials and plasma biomarkers like phosphorylated tau showed promise for clinical use. Biomarkers of amyloid beta, tau, neurodegeneration, inflammation, and others were prognostic with individualized prediction algorithms available online. Studies supported the amyloid cascade, emphasized the importance of neuroinflammation, and detailed widespread heterogeneity in disease, linked to genetic and vascular risk, co‐pathologies, sex, and resilience. Biological subtypes were consistently observed. Generalizability of ADNI results is limited by lack of cohort diversity, an issue ADNI‐4 aims to address by enrolling a diverse cohort.
A Prospective, Multicenter, Observational Study of Surgical vs Nonsurgical Management for Pituitary Apoplexy
Mamelak, Adam N. , Little, Andrew S. , Gardner, Paul A. , Kshettry, Varun R. , Jane, John A. , Barkhoudarian, Garni , Dodd, Robert , Mukherjee, Debraj , Gersey, Zachary C. , Fukuhara, Noriaki , Nishioka, Hiroshi , Kim, Eui Hyun , Litré, Claude‐Fabien, Sina, Elliott, Mazer, Mia W, Cui, Yujie , Bonert, Vivien, Nishioka, Hiroshi , Mukherjee, Debraj , Almeida, João Paulo , Recinos, Pablo F. , Soni, Pranay , Kelly, Daniel F. , Mazer, Mia, Bonert, Vivien S.

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | September 9, 2023 | Volume: 109 | Issue: 2 | Pages: e711-e725

10.1210/clinem/dgad541 | PMID 37698130 Get It

Abstract Context Pituitary apoplexy (PA) has been traditionally considered a neurosurgical emergency, yet retrospective single-institution studies suggest similar outcomes among patients managed medically. Objective We established a multicenter, international prospective registry to compare presentation and outcomes in PA patients treated with surgery or medical management alone. Methods A centralized database captured demographics, comorbidities, clinical presentation, visual findings, hormonal status, and imaging features at admission. Treatment was determined independently by each site. Key outcomes included visual, oculomotor, and hormonal recovery, complications, and hospital length of stay. Outcomes were also compared based on time from symptom onset to surgery, and from admission or transfer to the treating center. Statistical testing compared treatment groups based on 2-sided hypotheses and P less than .05. Results A total of 100 consecutive PA patients from 12 hospitals were enrolled, and 97 (67 surgical and 30 medical) were evaluable. Demographics, clinical features, presenting symptoms, hormonal deficits, and imaging findings were similar between groups. Severe temporal visual field deficit was more common in surgical patients. At 3 and 6 months, hormonal, visual, and oculomotor outcomes were similar. Stratifying based on severity of visual fields demonstrated no difference in any outcome at 3 months. Timing of surgery did not affect outcomes. Conclusion We found that medical and surgical management of PA yield similar 3-month outcomes. Although patients undergoing surgery had more severe visual field deficits, we could not clearly demonstrate that surgery led to better outcomes. Even without surgery, apoplectic tumor volumes regress substantially within 2 to 3 months, indicating that surgery is not always needed to reduce mass effect.
Surgical Intervention for Primary B-cell Lymphoma of the Spine
Patel, Neal , Brown, Nolan J. , Sahyouni, Ronald , Chan, Andrew K. , Chen, Selby , Lee, Seung-Jin, Gendreau, Julian , Lee, Seung Jin , Clifton, William

Mayo Clinic

Clinical Spine Surgery | September 9, 2023 | Volume: 37 | Issue: 7 | Pages: 296-304

10.1097/bsd.0000000000001522 | PMID 37684726 Get It

Study Design: Systematic review and meta-analysis. Objective: To perform a systematic review of the clinical symptoms, radiographic findings, and outcomes after spinal decompression in B-cell lymphoma. Summary of Background Data: B-cell lymphoma is a potential cause of spinal cord compression that presents ambiguously with nonspecific symptoms and variable imaging findings. Surgical decompression is a mainstay for both diagnosis and management, especially in patients with acute neurological deficits; however, the efficacy of surgical intervention compared with nonoperative management is still unclear. Methods: The databases of Medline, PubMed, and the Cochrane Database of Systemic Reviews were queried for all articles reporting spinal B-cell lymphoma. Data on presenting symptoms, treatments, survival outcomes, and histologic markers were extracted. Using the R software “survival” package, we generated bivariate and multivariate Cox survival regression models and Kaplan-Meier curves. Results: In total, 65 studies were included with 72 patients diagnosed with spinal B-cell lymphoma. The mean age was 56.22 (interquartile range: 45.00–70.25) with 68% of patients being males and 4.2% of patients being immunocompromised. Back pain was the most common symptom (74%), whereas B symptoms and cauda equina symptoms were present in 6% and 29%, respectively. The average duration of symptoms before presentation was 3.81 months (interquartile range: 0.45–3.25). The most common location was the thoracic spine (53%), with most lesions being hyperintense (28%) on T2 magnetic resonance imaging. Surgical resection was performed in 83% of patients. Symptoms improved in 91% of patients after surgery and in 80% of patients treated nonoperatively. For all 72 patients, the overall survival at 1 and 5 years was 85% (95% CI: 0.749–0.953; n = 72) and 66% (95% CI: 0.512–0.847; n = 72), respectively. Conclusion: Although surgery is usually offered in patients with acute spinal cord compression from B-cell lymphoma, chemotherapy and radiation alone offer a hopeful alternative to achieve symptomatic relief, particularly in patients who are unable to undergo surgery.
P14.07.B CELL-FREE DNA IN LONGITUDINALLY-ACQUIRED CEREBROSPINAL FLUID FOR DISEASE MONITORING
Riviere-Cazaux, Cécile , Mo, Wei , Dong, X, Warrington, A.P., Dong, X, Luo, Sheng , Wang, Andrew Zhuang , Du, P, Ghadimi, K, Warrington, A, Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii106-ii107

10.1093/neuonc/noad137.358 Get It

Abstract BACKGROUND Few methods exist via which to assess treatment response with high fidelity in gliomas. Cell-free DNA (cfDNA) is of growing interest as a liquid biomarker in plasma and CSF and has been used in other cancer types to optimize therapeutic regimens for individual patients. While CSF has previously been used as a source of cfDNA for gliomas, it remains unknown how cfDNA abundance and sequencing change throughout treatment and inevitable recurrence. To that end, we leveraged our growing biobank of longitudinal CSF specimens, acquired via CSF access devices, to determine the potential utility of CSF cfDNA as a monitoring tool for treatment response in patients with gliomas. MATERIAL AND METHODS Longitudinal CSF specimens were acquired via Ommaya reservoirs (NCT04692337) or ventriculoperitoneal shunts (NCT04692324) in patients with brain tumors, including gliomas. cfDNA was extracted from 1-5 mL of CSF based on available sample volumes and quantified via Qubit. Next-Generation sequencing (PredicineCARE) or low-pass whole genome sequencing (LPWGS) was performed by Predicine, Inc based on the amount of cfDNA available. RESULTS CSF acquired prior to versus after resection demonstrated an increase in quantified cfDNA (2.97x, range: 1.58-5.26x), consistent with the impact of increased parenchymal disruption and closer contact with CSF. Thereafter, CSF cfDNA continued to decrease throughout chemoradiation and adjuvant treatment and increased at recurrence, including in patients co-enrolled in immunotherapy trials for IL-7 agonists and pembrolizumab. Interestingly, copy number burden (CNB) increased by the time of recurrence in three patients with known disease progression, and continued to decrease throughout immunotherapy treatment in one patient despite concerns of pseudoprogression. In one patient with a hypermutated glioblastoma, CSF cfDNA revealed over 59 genomic alterations, including MAP2K1, KIT, and PDGFRA, and over 100 more variants of unknown significance, each of which had been detected in sequencing of the tissue acquired at resection and subsequently decreased with chemoradiation. In another patient with a known progressing EGFR-amplified GBM, over 200 new variants were identified by the patient’s final sample and EGFR copy number increased from 2 to over 30. CONCLUSION Analysis of cfDNA over a patient’s disease course, including resection and treatment with standard-of-care and experimental therapies, may be of use for disease monitoring and treatment response. Further work is needed to evaluate these findings in a larger cohort of patients and to determine the sensitivity of changes in mutations, CNB, and cfDNA quantity for glioma disease burden.
OS09.4.A RANO 2.0: UPDATE TO THE RESPONSE ASSESSMENT IN NEURO-ONCOLOGY (RANO) CRITERIA FOR HIGH- AND LOW-GRADE GLIOMAS IN ADULTS
Wen, Patrick Y. , Youssef, George , Barboriak, Daniel P. , DeGroot, John, Lassman, Andrew B. , Molinaro, Annette M. , Rahman, Rifaquat , Shankar, Lalitha , Sul, Joohee, Villanueva‐Meyer, Javier , Macdonald, David , Reardon, David A. , Vogelbaum, Michael A. , Chang, Susan M. , Barboriak, Daniel P , Wen, Patrick Yung , Bent, Martin J. van den , Youssef, G, Cloughesy, Timothy F. , Ellingson, Benjamin M. , Weller, Michael , Galanis, Evanthia , Gilbert, Mark R. , Huang, Raymond Y. , Mehta, Minesh P. , Molinaro, Annette M. , Preusser, Matthias , Stupp, Roger , Villanueva-Meyer, Javier E. , Wick, Wolfgang

Mayo Clinic

Neuro-Oncology | September 8, 2023 | Volume: 25 | Issue: Supplement_2 | Pages: ii21-ii21

10.1093/neuonc/noad137.061 Get It

Abstract BACKGROUND The Response Assessment in Neuro-Oncology (RANO) criteria for high-grade gliomas (RANO-HGG) and low-grade gliomas (RANO-LGG) were developed to improve reliability of response assessment in glioma trials. Over time some limitations of these criteria were identified, and uncertainty emerged regarding integrating features of the modified RANO (mRANO) or the immunotherapy RANO (iRANO) criteria. MATERIAL AND METHODS Informed by data from a cohort of glioblastoma patients and other evaluations of RANO criteria that allowed evaluation of features of the different criteria, the RANO working group developed updates to the RANO criteria (RANO 2.0). RESULTS Based on the 2021 WHO classification of gliomas, we recommend a standard set of criteria for both high and low-grade gliomas, to be used for all trials regardless of the treatment modalities being evaluated. In the newly diagnosed setting, the post-radiotherapy MRI, rather than the post-surgical MRI, will be used as the baseline for future comparison. Since the incidence of pseudoprogression is high in the 12 weeks following radiotherapy, continuation of treatment and confirmation of progression during this period with a repeat MRI, or histopathologic evidence of unequivocal recurrent tumor, is required to define tumor progression. However, confirmation scans are not mandatory after this period nor for recurrent tumors. For treatments with a high likelihood of pseudoprogression, mandatory confirmation of progression with a repeat MRI is highly recommended. The primary measurement remains the maximum cross-sectional area of tumor (2-dimensional) but volumetric measurements are an option. For IDH-wildtype glioblastoma, the non-enhancing disease will no longer be evaluated. In IDH-mutated tumors with a significant non-enhancing component, clinical trials may require evaluating both the enhancing and non-enhancing tumor components for response assessment. CONCLUSION These criteria represent a work in progress that will hopefully improve the assessment of response in glioma trials. Future updates will incorporate novel developments, advanced imaging techniques, and endpoints as they become validated.
Hydrophilic polymer embolus in the bone marrow
Rangan, Aruna , Norgan, Andrew P. , Norgan, Andrew P

Mayo Clinic

Blood | September 7, 2023 | Volume: 142 | Issue: 10 | Pages: 939-939

10.1182/blood.2023021763 | PMID 37676692 Get It

The Global, Regional, and National Burden of Adult Lip, Oral, and Pharyngeal Cancer in 204 Countries and Territories
Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Compton, Kelly, Xu, Rixing, Mishra, Rashmi , Drangsholt, Mark, Antunes, José Leopoldo Ferreira , Acheson, Alistair, Lu, Dan , Wallace, Lindsey E., Kocarnik, Jonathan , Fu, Weijia , Dean, Frances , Pennini, Alyssa, Henrikson, Hannah , Alam, Shazia , Ababneh, Emad , Abdoun, Meriem , Abidi, Hassan , Ali, Hiwa Abubaker, Adane, Tigist Demssew , Ahmad, Aqeel , Rashid, Tarik A. , Hamad, Hanadi Al , Alahdab, Fares , Alimohamadi, Yousef, Alipour, Vahid, Anwar, Sumadi Lukman, Anyasodor, Anayochukwu Edward , Aravkin, Aleksandr Y. , Aruleba, Raphael Taiwo , Azadnajafabad, Sina , Azangou‐Khyavy, Mohammadreza , Badar, Muhammad , Barqawi, Hiba Jawdat , Bashir, Nasir Zeeshan , Bashiri, Azadeh, Benzian, Habib , Bhagat, Devidas S. , Bhojaraja, Vijayalakshmi S, Bouaoud, Souad, Braithwaite, Dejana , Брико, Н. И. , Chakraborty, Promit Ananyo , Chattu, Vijay Kumar , Chaurasia, Akhilanand , Chen, Mengxuan , Cho, William C. , Chu, Dinh‐Toi , Chukwu, Isaac Sunday , Chung, Eunice, Martins, Natália , Dadras, Omid , Dandona, Lalit , Dandona, Rakhi , Daneshpajouhnejad, Parnaz , Molla, Meseret Derbew , Dessalegn, Fikadu Nugusu, Digesa, Lankamo Ena , Dixit, Shilpi Gupta , Dixit, Abhinav , Djalalinia, Shirin , Tantawi, Maha El , Enyew, Daniel Berhanie, Erku, Daniel , Ezzeddini, Rana, Fagbamigbe, Adeniyi Francis , Falzone, Luca , Fetensa, Getahun, Fukumoto, Takeshi , Gebrehiwot, Mesfin , Ghashghaee, Ahmad , Golechha, Mahaveer , Goleij, Pouya , Gorini, Giuseppe , Guimarães, André Luiz Sena , Gupta, Sapna , Halboub, Esam , Hanif, Asif , Harorani, Mehdi , Hasani, Hamidreza, Hassan, Abbas M. , Hassen, Mohammed Bheser, Hay, Simon I , Herrera-Serna, Brenda Yuliana , Hosseinzadeh, Mehdi , Ilić, Irena , Isola, Gaetano , Jaiswal, Abhishek , Jani, Chinmay , Javaheri, Tahereh , Jayaram, Shubha, Joseph, Nitin , Kadashetti, Vidya, Karanth, Shama D. , Kaur, Harkiran , Keykhaei, Mohammad , Khader, Yousef , Khajuria, Himanshu , Khanali, Javad , Khatib, Mahalaqua Nazli , Kashani, Hamid Reza Khayat , Kim, Min Seo , Kompani, Farzad , Kurmi, Om , Lal, Dharmesh Kumar, Lee, Yo Han , Lim, Stephen S , Listl, Stefan , Lopukhov, Platon D , Mafi, Ahmad R , Malik, Ahmad Azam , Maulud, Sazan Qadir , Nasab, Entezar Mehrabi, Mirfakhraie, Reza , Misganaw, Awoke, Misra, Sanjeev , Mithra, Prasanna , Mohammad, Yousef , Moni, Mohammad Ali , Moraga, Paula , Mubarik, Sumaira , Murray, Christopher J L , Swamy, Sreenivas Narasimha, Narayana, Aparna Ichalangod, Nassereldine, Hasan , Natto, Zuhair S. , Nayak, Biswa Prakash , Negru, Șerban , Nggada, Haruna Asura , Núñez-Samudio, Virginia , Oancea, Bogdan , Padrón‐Monedero, Alicia , Pandey, Anamika , Patel, Jay , Pezzani, Raffaele , Piracha, Zahra Zahid , Rabiee, Navid , Radhakrishnan, Venkatraman , Rahmani, Amir M. , Rao, Sowmya J, Rath, Goura Kishor, Rawaf, David Laith , Rawassizadeh, Reza , Rezaei, Nazila, Rezapour, Aziz , Riad, Abanoub , Romero‐Rodríguez, Esperanza , Manjula, S, Chandan, S N , Saddik, Basema , Saeed, Umar , Safaei, Mohsen , Sahebazzamani, Maryam , Samy, Abdallah M , Santric-Milicevic, Milena M , Sathian, Brijesh , Satpathy, Maheswar , Šekerija, Mario , Senthilkumaran, Subramanian , Seylani, Allen, Shafaat, Omid , Sharew, Mequannent Melaku Sharew, Sharifi‐Rad, Javad , Shorofi, Seyed Afshin, Shrestha, Sunil , Malleshappa, Sudeep K Siddappa , Singh, Paramdeep , Sinha, Dhirendra Narain , Solomon, Yonatan , Suleman, Muhammad , Abdulkader, Rizwan Suliankatchi , Abkenar, Yasaman Taheri, Tan, Ker‐Kan , Tbakhi, Abdelghani, Thiyagarajan, Arulmani , Tovani‐Palone, Marcos Roberto , Volovăț, Simona Ruxandra , Westerman, Ronny, Wickramasinghe, Nuwan Darshana , Xiao, Hong , Zadnik, Vesna, Zare, Iman, Zhang, Zhi-Jiang , Force, Lisa M , Hugo, Fernando Neves , Hoogar, Praveen , Rezaei, Nazila , Rezaei, Nazila , Shivakumar, KM , Collaborators, GBD 2019 Lip, Oral, and Pharyngeal Cancer, Cunha, Amanda Ramos da , Kerr, Alexander Ross , Wallace, Lindsey E., Abd‐Elsalam, Sherief , Abu‐Gharbieh, Eman , Addo, Isaac Yeboah , Ahmad, Sajjad , Akonde, Maxwell , Al‐Maweri, Sadeq Ali , Alsharif, Ubai , Ansari‐Moghaddam, Alireza , Anwar, Sumadi Lukman, Arabloo, Jalal , Asaad, Malke, Ashraf, Tahira , Athari, Seyyed Shamsadin , Attia, Sameh , Baghcheghi, Nayereh , Banach, Maciej , Bardhan, Mainak , Bernabé, Eduardo , Bjørge, Tone , Călina, Daniela Cornelia , Carreras, Giulia , Dai, Xiaochen , Soltani, Reza Darvishi Cheshmeh , Darwesh, Aso Mohammad , Debela, Sisay Abebe , Dianatinasab, Mostafa , Sayed, Iman El , Gaewkhiew, Piyada , Gallus, Silvano , Gill, Paramjit Singh , Gomez, Ricardo Santiago , Gupta, Bhawna , Gupta, Veer Bala , Gupta, Vivek , Haj‐Mirzaian, Arvin , Halwani, Rabih , Hariyani, Ninuk , Hassanipour, Soheil , Hayat, Khezar , Holla, Ramesh , Horita, Nobuyuki , Hussain, Salman , Ilesanmi, Olayinka Stephen , Ilić, Milena , Jayarajah, Umesh , Kandaswamy, Eswar , Karaye, Ibraheem M. , Kauppila, Joonas H. , Tabari, Mohammad Amin Khazeei , Koohestani, Hamid Reza , Kumar, G Anil , Vecchia, Carlo La , Lal, Dharmesh Kumar, Landires, Iván , Lasrado, Savita , Ledda, Caterina , Libra, Massimo , Mahumud, Rashidul Alam , Mathur, Manu Raj , Meena, Jitendra Kumar , Meštrović, Tomislav , Mohammadi, Mokhtar, Mohammadi, Esmaeil , Mokdad, Ali H. , Morrison, Shane D. , Mozaffari, Hamid Reza , Nair, Tapas Sadasivan , Nouraei, Hasti , Olagunju, Andrew T , Bali, Ahmed Omar , Padubidri, Jagadish Rao , Pardhan, Shahina , Radhakrishnan, Raghu , Rahmani, Amir Masoud, Rahmanian, Vahid , Rao, Chythra R , Rawaf, Salman , Razeghinia, Mohammad Sadegh , Rezaei, Negar , Rezaei, Nima , Rezapour, Aziz , Roberts, Thomas J. , Roshandel, Gholamreza , Saeb, Mohammad Reza , Sahebkar, Amirhossein , Farrokhi, Amir Salek , Shahsavari, Hamid R. , Shamsoddin, Erfan , Shetty, Jeevan K. , Shivakumar, K. M. , Shobeiri, Parnian , Singh, Jasvinder A. , Singh, Garima Prateek , Talaat, Iman Mamdouh , Tiyuri, Amir , Unnikrishnan, Bhaskaran , Vo, Bay, Wang, Cong , Yu, Chuanhua , Yüce, Deniz , Yunusa, Ismaeel , Zoladl, Mohammad , Alahdab, Fares

Mayo Clinic

JAMA Oncology | September 7, 2023 | Volume: 9 | Issue: 10 | Pages: 1401

10.1001/jamaoncol.2023.2960 | PMID 37676656 Get It

ImportanceLip, oral, and pharyngeal cancers are important contributors to cancer burden worldwide, and a comprehensive evaluation of their burden globally, regionally, and nationally is crucial for effective policy planning.ObjectiveTo analyze the total and risk-attributable burden of lip and oral cavity cancer (LOC) and other pharyngeal cancer (OPC) for 204 countries and territories and by Socio-demographic Index (SDI) using 2019 Global Burden of Diseases, Injuries, and Risk Factors (GBD) Study estimates.Evidence ReviewThe incidence, mortality, and disability-adjusted life years (DALYs) due to LOC and OPC from 1990 to 2019 were estimated using GBD 2019 methods. The GBD 2019 comparative risk assessment framework was used to estimate the proportion of deaths and DALYs for LOC and OPC attributable to smoking, tobacco, and alcohol consumption in 2019.FindingsIn 2019, 370 000 (95% uncertainty interval [UI], 338 000-401 000) cases and 199 000 (95% UI, 181 000-217 000) deaths for LOC and 167 000 (95% UI, 153 000-180 000) cases and 114 000 (95% UI, 103 000-126 000) deaths for OPC were estimated to occur globally, contributing 5.5 million (95% UI, 5.0-6.0 million) and 3.2 million (95% UI, 2.9-3.6 million) DALYs, respectively. From 1990 to 2019, low-middle and low SDI regions consistently showed the highest age-standardized mortality rates due to LOC and OPC, while the high SDI strata exhibited age-standardized incidence rates decreasing for LOC and increasing for OPC. Globally in 2019, smoking had the greatest contribution to risk-attributable OPC deaths for both sexes (55.8% [95% UI, 49.2%-62.0%] of all OPC deaths in male individuals and 17.4% [95% UI, 13.8%-21.2%] of all OPC deaths in female individuals). Smoking and alcohol both contributed to substantial LOC deaths globally among male individuals (42.3% [95% UI, 35.2%-48.6%] and 40.2% [95% UI, 33.3%-46.8%] of all risk-attributable cancer deaths, respectively), while chewing tobacco contributed to the greatest attributable LOC deaths among female individuals (27.6% [95% UI, 21.5%-33.8%]), driven by high risk-attributable burden in South and Southeast Asia.Conclusions and RelevanceIn this systematic analysis, disparities in LOC and OPC burden existed across the SDI spectrum, and a considerable percentage of burden was attributable to tobacco and alcohol use. These estimates can contribute to an understanding of the distribution and disparities in LOC and OPC burden globally and support cancer control planning efforts.